The impact of the suppression of highly connected protein interactions on the corona virus infection.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

COVID-19* ; Influenza A Virus, H1N1 Subtype*/metabolism ; Virus Diseases* ; Viruses*/metabolism; Antiviral Agents/metabolism ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19 Vaccines ; Humans ; SARS-CoV-2 ; Viral Proteins/metabolism

Several highly effective Covid-19 vaccines are in emergency use, although more-infectious coronavirus strains, could delay the end of the pandemic even further. Because of this, it is highly desirable to develop fast antiviral drug treatments to accelerate the lasting immunity against the virus. From a theoretical perspective, computational approaches are useful tools for antiviral drug development based on the data analysis of gene expression, chemical structure, molecular pathway, and protein interaction mapping. This work studies the structural stability of virus-host interactome networks based on the graphical representation of virus-host protein interactions as vertices or nodes connected by commonly shared proteins. These graphical network visualization methods are analogous to those use in the design of artificial neural networks in neuromorphic computing. In standard protein-node-based network representation, virus-host interaction merges with virus-protein and host-protein networks, introducing redundant links associated with the internal virus and host networks. On the contrary, our approach provides a direct geometrical representation of viral infection structure and allows the effective and fast detection of the structural robustness of the virus-host network through proteins removal. This method was validated by applying it to H1N1 and HIV viruses, in which we were able to pinpoint the changes in the Interactome Network produced by known vaccines. The application of this method to the SARS-CoV-2 virus-host protein interactome implies that nonstructural proteins nsp4, nsp12, nsp16, the nuclear pore membrane glycoprotein NUP210, and ubiquitin specific peptidase USP54 play a crucial role in the viral infection, and their removal may provide an efficient therapy. This method may be extended to any new mutations or other viruses for which the Interactome Network is experimentally determined. Since time is of the essence, because of the impact of more-infectious strains on controlling the spread of the virus, this method may be a useful tool for novel antiviral therapies.
(© 2022. The Author(s).)

Oncotarget. 2017 Feb 14;8(7):10765-10766. (PMID: 28129647)
Front Microbiol. 2012 Dec 21;3:428. (PMID: 23267356)
Proc Natl Acad Sci U S A. 2000 Apr 11;97(8):4309-14. (PMID: 10725408)
Clin Microbiol Rev. 2013 Jul;26(3):476-92. (PMID: 23824369)
Biochim Biophys Acta Mol Basis Dis. 2020 Oct 1;1866(10):165878. (PMID: 32544429)
Nat Commun. 2015 Oct 20;6:8627. (PMID: 26482121)
Vaccine. 1997 Aug-Sep;15(12-13):1372-8. (PMID: 9302747)
Cell. 2020 Apr 16;181(2):271-280.e8. (PMID: 32142651)
Acta Pharm Sin B. 2020 May;10(5):766-788. (PMID: 32292689)
Viruses. 2010 Aug;2(8):1804-20. (PMID: 21994708)
Vaccine. 2021 Jun 29;39(29):3852-3861. (PMID: 34099325)
J Virol. 2005 Oct;79(20):12905-13. (PMID: 16188992)
Proc Natl Acad Sci U S A. 2017 May 23;114(21):E4251-E4260. (PMID: 28484023)
Int J Mol Sci. 2017 Jul 18;18(7):. (PMID: 28718801)
J Mol Biol. 2003 Aug 29;331(5):991-1004. (PMID: 12927536)
N Engl J Med. 2020 Feb 20;382(8):727-733. (PMID: 31978945)
Nature. 1999 Jul 8;400(6740):107-9. (PMID: 10428673)
J Virol. 1989 Sep;63(9):4110-4. (PMID: 2474678)
J Virol. 2009 Oct;83(19):10314-8. (PMID: 19640993)
J Med Virol. 2020 May;92(5):522-528. (PMID: 32027036)
J Virol. 2004 Dec;78(24):13600-12. (PMID: 15564471)
Acta Pharmacol Sin. 2020 Sep;41(9):1141-1149. (PMID: 32747721)
Nat Commun. 2020 Jul 24;11(1):3717. (PMID: 32709887)
Front Microbiol. 2021 Jan 25;11:592908. (PMID: 33746908)
Antiviral Res. 2015 Mar;115:21-38. (PMID: 25554382)
Virol J. 2019 May 27;16(1):69. (PMID: 31133031)
Virusdisease. 2021 Mar;32(1):46-54. (PMID: 33758772)
mSystems. 2019 Apr 9;4(2):. (PMID: 30984872)
Nat Struct Mol Biol. 2005 Nov;12(11):980-6. (PMID: 16228002)
Methods. 2021 Nov;195:44-56. (PMID: 33639316)
J Biomol Struct Dyn. 2021 Aug;39(13):4633-4646. (PMID: 32573355)
Curr Opin Struct Biol. 2017 Jun;44:31-38. (PMID: 27866112)
Nat Commun. 2019 May 28;10(1):2342. (PMID: 31138817)
J Virol. 2014 Nov;88(21):12511-27. (PMID: 25142582)
mBio. 2013 Aug 13;4(4):. (PMID: 23943763)
Nat Immunol. 2021 Oct;22(10):1199-1200. (PMID: 34556875)
Virology. 2017 Oct;510:165-174. (PMID: 28738245)
Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3257-62. (PMID: 10077671)
Viruses. 2020 Mar 25;12(4):. (PMID: 32218151)
Sci China Life Sci. 2020 Sep;63(9):1413-1416. (PMID: 32291557)
PLoS One. 2013 Apr 29;8(4):e62416. (PMID: 23658627)
Int J Surg. 2020 Sep;81:1-8. (PMID: 32730205)
Adv Virus Res. 2016;96:59-126. (PMID: 27712628)
J Virol. 2000 Jun;74(11):5213-23. (PMID: 10799597)
Proteomics. 2016 Aug;16(15-16):2238-45. (PMID: 27119218)
Acta Crystallogr D Biol Crystallogr. 2009 Aug;65(Pt 8):839-46. (PMID: 19622868)
Virol J. 2009 Jun 18;6:79. (PMID: 19534833)
Annu Rev Genet. 2012;46:677-700. (PMID: 23145935)
Trends Microbiol. 2016 Jun;24(6):490-502. (PMID: 27012512)
J Virol. 2006 Aug;80(16):7894-901. (PMID: 16873246)
J Virol. 2007 Apr;81(7):3151-61. (PMID: 17202208)
Eur J Hum Genet. 2016 Oct;24(10):1388-95. (PMID: 27071718)
EMBO J. 2002 Jul 1;21(13):3213-24. (PMID: 12093723)
J Med Virol. 2020 Apr;92(4):418-423. (PMID: 31967327)
Autophagy. 2014 Aug;10(8):1426-41. (PMID: 24991833)
Nature. 2018 Nov;563(7733):676-680. (PMID: 30487615)
J Virol. 2012 Jul;86(14):7565-76. (PMID: 22573863)
Front Genet. 2021 Mar 09;12:626642. (PMID: 33767730)
Cell Host Microbe. 2020 Mar 11;27(3):325-328. (PMID: 32035028)
J Mol Biol. 2009 Jan 9;385(1):212-25. (PMID: 18983849)
J Clin Med. 2020 Apr 01;9(4):. (PMID: 32244779)
J Virol. 1997 Apr;71(4):2772-8. (PMID: 9060631)
Nature. 2004 Jul 1;430(6995):88-93. (PMID: 15190252)
Curr Protoc Bioinformatics. 2015 Mar 09;49:8.19.1-8.19.16. (PMID: 25754993)
Front Immunol. 2021 May 11;12:662565. (PMID: 34046034)
Pharmacol Res. 2020 Jul;157:104859. (PMID: 32360480)
Heliyon. 2021 Mar;7(3):e06387. (PMID: 33688584)
J Virol. 2001 Jun;75(12):5656-62. (PMID: 11356973)
Proc Natl Acad Sci U S A. 2011 Jun 28;108(26):10538-43. (PMID: 21680884)
Sci Rep. 2020 Mar 11;10(1):4481. (PMID: 32161317)
Int J Mol Sci. 2017 Jan 10;18(1):. (PMID: 28075409)
Front Microbiol. 2017 Aug 17;8:1557. (PMID: 28861068)
Biochem Soc Trans. 2008 Dec;36(Pt 6):1398-403. (PMID: 19021563)
Nature. 2020 Jul;583(7816):459-468. (PMID: 32353859)
Cell Host Microbe. 2015 Dec 9;18(6):723-35. (PMID: 26651948)
J Virol. 1996 Sep;70(9):6083-96. (PMID: 8709232)
Vaccine. 2009 Nov 5;27 Suppl 4:D65-8. (PMID: 19837290)
Science. 2020 Dec 4;370(6521):. (PMID: 33060197)

0 (Antiviral Agents)
0 (COVID-19 Vaccines)
0 (Viral Proteins)

Date Created: 20220602 Date Completed: 20220606 Latest Revision: 20220728

20231215

PMC9160517

10.1038/s41598-022-13373-0

35654986